Latest Breaking News On - Proteinuric glomerular diseases - Page 1 : comparemela.com

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company s IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1%.

United statesJonathan grahamMarlena abdinoorSloan simpsonLoreto mdaParag mahantiLambers heerspinkBartonm endothelinMichael meoNovartis fabhaltaPrnewswire novartisEuropean renal associationFibrotic transcriptional networksNovartis pharmaceuticals corporationExchange commissionEndpoint analysis

Novartis atrasentan Phase III data show clinically

Novartis atrasentan Phase III data show clinically
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesLambers heerspinkSloan simpsonMichael meoSatoshi sugimotoJonathan grahamImke kappesMarlena abdinoorLoreto mdaBartonm endothelinNicole zinsli sommParag mahantiIsabella zinckNovartis fabhaltaEuropean renal associationExchange commission

Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company s IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs.

United statesSloan simpsonNicole zinsli sommLambers heerspinkJonathan grahamSatoshi sugimotoParag mahantiMarlena abdinoorImke kappesIsabella zinckNovartis fabhaltaMichael meoLoreto mdaBartonm endothelinExchange commissionEuropean renal association

Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023

SEATTLE, March 23, 2023 Chinook Therapeutics, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today. | March 23, 2023

United kingdomGyeonggi doKyonggi doSouth koreaKrung thep mahanakhonJonathan barrattHiddojl heerspinkGyun kimChinook therapeutics incGlobenewswire incHallym university sacred heart hospitalInvestor relations corporate communicationsUniversity medical center groningenUniversity of leicesterWorld congressPlacebo controlled study

Chinook Therapeutics (KDNY) Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort

Chinook Therapeutics (KDNY) Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBaylor college of medicineEric dobmeierLaura kooiengaNoopur liffickSreedhara mandayamUniversity of texas md anderson cancer centerChinook therapeutics incInvestor relations corporate communicationsIga nephropathyInterim resultsSingle nucleiReveals cell type specific responsesPlacebo controlled studyProteinuric glomerular diseasesHealthy volunteers